Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
about
HIV Associated Neurocognitive DisordersHeterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studiesTrue story about HIV: theory of viral sequestration and reserve infectionHIV competition dynamics over sexual networks: first comer advantage conserves founder effects.The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study.Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis.The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness.Human immunodeficiency virus type 2 in two Saudi families.Gender differences in the rates and correlates of HIV risk behaviors among drug abusers.Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission.Changing HIV epidemics: what HIV-2 can teach us about ending HIV-1.Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support.Tits and bits of HIV Tat protein.Curcumin and its analogues: a potential natural compound against HIV infection and AIDS.Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea-Bissau.Metabolic profiling during HIV-1 and HIV-2 infection of primary human monocyte-derived macrophages.Molecular dynamics and MM/GBSA-integrated protocol probing the correlation between biological activities and binding free energies of HIV-1 TAR RNA inhibitors.Ficolin-2 binds to HIV-1 gp120 and blocks viral infection.Infectiousness of HIV-infected homosexual men in the era of highly active antiretroviral therapy.Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2.Hydroxyethylamine derivatives as HIV-1 protease inhibitors: a predictive QSAR modelling study based on Monte Carlo optimization.
P2860
Q27023968-0426CD79-C204-4A80-9BCE-778DF87382C3Q28307869-9D673050-9DA8-4214-A714-56986C2DAF36Q28732833-526FB3B1-B95E-4841-9DD8-13D9D155282DQ30371471-D3E6B2F0-B354-48F0-8CB5-C9D650820113Q33884059-816DEAEE-F184-4845-90DC-B11F8775FA77Q34793224-B0EB0D1D-D94A-4E90-989A-58B75FD2559DQ34804928-30F89911-DB13-422E-927A-FDFC6386975DQ34885559-B75C066A-4610-4628-8530-840C5BA0F901Q35165841-195C357E-9D36-40F1-B62B-932B55F95794Q35203629-6CC46F88-D13F-437B-8389-3AFFBD3F1E69Q35857522-FC3EBACA-D958-48D5-80D7-A0F28E60231AQ37052996-5818D866-7331-4746-B223-8790AAF2D3FEQ37053007-CE229877-35F6-47BB-A31D-AED63C1B83C6Q37053027-970F0C95-69F3-4EEF-AAD5-A337A92CC442Q37083896-BAE40635-6BE7-4AE1-AD35-6D505282A068Q37102101-1964C60F-9D5B-4EAE-BFD2-41FF09B52173Q37307096-F1C8BB0F-1904-440D-BE1C-EEDB6843500CQ37517645-591D3C51-44A1-49E6-BA8A-AF92B74C8190Q37825906-2623B3EE-7D03-4208-A312-67D086821648Q38592538-E062820D-E7B4-45A1-9C12-88D05119C918Q39437445-743885E0-3F56-463E-9A20-BFDBC561D5FAQ39983923-569EAEB9-65B5-4F5B-8C52-44E818C29463Q40374329-313A5586-E580-43A7-A7B2-DCD1958015F1Q40557897-C52A0A6F-37A3-4985-81D9-E8F1D043AE84Q42407728-262C2606-13B3-473A-A1B0-F554E56101ADQ46874552-16B82407-0DD5-4767-8B6A-F1D09C4EDBBDQ48125556-97CF0979-FE6C-4B0D-BA50-3AB49101ED6A
P2860
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@ast
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@en
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@en-gb
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@nl
type
label
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@ast
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@en
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@en-gb
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@nl
prefLabel
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@ast
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@en
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@en-gb
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@nl
P2093
P2860
P356
P1476
Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
@en
P2093
Aissatou Guéye-NDiaye
Christopher Mullins
Geoffrey Eisen
Ian W. McKeague
Peter B. Gilbert
Phyllis J. Kanki
P2860
P304
P356
10.1002/SIM.1342
P407
P577
2003-01-28T00:00:00Z